The United States appears to have reached its peak obesity levels, as indicated by a recent survey prompting speculation about the potential influence of weight-loss drugs like Ozempic. The latest data reveals a 2 percent decrease in the obesity rate among American adults between 2020 and 2023, according to findings from a US National Health and Nutrition Examination survey released towards the end of last month.
While a direct correlation between the decline in obesity rates and the use of weight-loss medications such as Wegovy and Ozempic has not been definitively established, there is a strong indication that these drugs, which entered the market around 2021, are playing a significant role. It is estimated that around one in eight US adults have experimented with weight loss drugs, with over 15 million individuals currently using prescription options. Novo Nordisk, the manufacturer of Wegovy, reported to Fox Business in May that approximately 25,000 Americans were commencing this drug on a weekly basis.
An analysis of data from 2020 to 2023, released in May, noted a substantial 594 percent rise in the monthly usage of these new-generation weight loss drugs among young adults and teenagers. Concurrently, recent survey results indicate a more rapid decline in obesity rates among individuals with college degrees, as interpreted from the data by The Financial Times.
In the US, the statistics show that two in five adults and almost 15 million children and adolescents grapple with obesity. The prevalence of obesity increased by over 11 percent from the late 1990s up to 2020. Obesity is associated with elevated risks of various health conditions including certain cancers, stroke, heart disease, hypertension, Type 2 diabetes, and premature mortality.
The credibility of the recent National Health survey is bolstered by the fact that the weight and height measurements were taken by healthcare professionals rather than relying on self-reported figures. The weight-loss medications, initially intended for diabetes treatment, operate by simulating a natural hormone that can curb appetite. While Wegovy is among the FDA-approved drugs for weight loss, Ozempic is primarily sanctioned for managing Type 2 diabetes.
Overall, the declining trend in obesity rates suggests a potential shift in the health landscape of the US population, influenced in part by the growing adoption of weight-loss drugs. The positive impact of these medications on combatting obesity underscores the importance of ongoing research and development in the healthcare and pharmaceutical sectors to address prevalent health concerns.